ARWR
Price
$27.80
Change
+$2.12 (+8.26%)
Updated
Sep 3 closing price
Capitalization
3.84B
88 days until earnings call
SYRE
Price
$16.81
Change
+$0.18 (+1.08%)
Updated
Sep 3 closing price
Capitalization
1.02B
63 days until earnings call
Interact to see
Advertisement

ARWR vs SYRE

Header iconARWR vs SYRE Comparison
Open Charts ARWR vs SYREBanner chart's image
Arrowhead Pharmaceuticals
Price$27.80
Change+$2.12 (+8.26%)
Volume$5.39M
Capitalization3.84B
Spyre Therapeutics
Price$16.81
Change+$0.18 (+1.08%)
Volume$293.94K
Capitalization1.02B
ARWR vs SYRE Comparison Chart in %
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. SYRE commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a StrongBuy and SYRE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (ARWR: $27.80 vs. SYRE: $16.83)
Brand notoriety: ARWR: Notable vs. SYRE: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 234% vs. SYRE: 53%
Market capitalization -- ARWR: $3.84B vs. SYRE: $1.02B
ARWR [@Biotechnology] is valued at $3.84B. SYRE’s [@Biotechnology] market capitalization is $1.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, ARWR is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 7 TA indicator(s) are bullish while SYRE’s TA Score has 6 bullish TA indicator(s).

  • ARWR’s TA Score: 7 bullish, 4 bearish.
  • SYRE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, both ARWR and SYRE are a good buy in the short-term.

Price Growth

ARWR (@Biotechnology) experienced а +27.58% price change this week, while SYRE (@Biotechnology) price change was -1.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.26%. For the same industry, the average monthly price growth was +15.05%, and the average quarterly price growth was +29.52%.

Reported Earning Dates

ARWR is expected to report earnings on Dec 01, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+0.26% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($3.84B) has a higher market cap than SYRE($1.02B). ARWR YTD gains are higher at: 47.872 vs. SYRE (-27.706). ARWR has higher annual earnings (EBITDA): -52.51M vs. SYRE (-222.15M). ARWR has more cash in the bank: 900M vs. SYRE (527M). SYRE has less debt than ARWR: SYRE (0) vs ARWR (353M). ARWR has higher revenues than SYRE: ARWR (573M) vs SYRE (0).
ARWRSYREARWR / SYRE
Capitalization3.84B1.02B378%
EBITDA-52.51M-222.15M24%
Gain YTD47.872-27.706-173%
P/E RatioN/A1.72-
Revenue573M0-
Total Cash900M527M171%
Total Debt353M0-
FUNDAMENTALS RATINGS
ARWR vs SYRE: Fundamental Ratings
ARWR
SYRE
OUTLOOK RATING
1..100
2210
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
3763
P/E GROWTH RATING
1..100
282
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SYRE's Valuation (72) in the Pharmaceuticals Major industry is in the same range as ARWR (94) in the Biotechnology industry. This means that SYRE’s stock grew similarly to ARWR’s over the last 12 months.

SYRE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ARWR (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to ARWR’s over the last 12 months.

SYRE's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as ARWR (97) in the Biotechnology industry. This means that SYRE’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's Price Growth Rating (37) in the Biotechnology industry is in the same range as SYRE (63) in the Pharmaceuticals Major industry. This means that ARWR’s stock grew similarly to SYRE’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for SYRE (82) in the Pharmaceuticals Major industry. This means that ARWR’s stock grew significantly faster than SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRSYRE
RSI
ODDS (%)
Bearish Trend 1 day ago
87%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
85%
Declines
ODDS (%)
Bearish Trend 16 days ago
83%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
85%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HACAX123.65N/A
N/A
Harbor Capital Appreciation Instl
JORIX20.58N/A
N/A
Janus Henderson Global Select S
ITFEX12.64N/A
N/A
Voya International High Div Low Vol S2
CAXCX18.81N/A
N/A
Catalyst/MAP Global Equity C
MVTRX11.71N/A
N/A
Transamerica Mid Cap Value Opps R6

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with DNLI. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
+8.26%
DNLI - ARWR
58%
Loosely correlated
-0.91%
IMNM - ARWR
53%
Loosely correlated
+10.67%
BEAM - ARWR
52%
Loosely correlated
+15.02%
RGNX - ARWR
52%
Loosely correlated
+8.22%
SYRE - ARWR
52%
Loosely correlated
+1.20%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with IDYA. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+1.20%
IDYA - SYRE
61%
Loosely correlated
+1.10%
CGON - SYRE
61%
Loosely correlated
+4.41%
BEAM - SYRE
58%
Loosely correlated
+15.02%
XNCR - SYRE
57%
Loosely correlated
-2.57%
CRNX - SYRE
56%
Loosely correlated
+4.17%
More